# Latent Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/latent-labs

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.latentlabs.com/
- Total disclosed funding: $40M
- Latest round: Series A (Dec 1, 2024)
- Investors on record: 7

## About

Latent Labs is a biotechnology company focused on developing generative AI technologies that enable programmable biology, particularly in molecular biology applications.Founded in 2023, Latent Labs specializes in generative AI models for molecular biology. The company raised USD 40.00 mn in Series A funding on February 12, 2025, co-led by Radical Ventures and Sofinnova Partners, with participation from Flying Fish Partners and Isomer Capital. The company is based in London, UK, with one deal recorded to date. The founder has not been specified, and no details regarding previous ventures are available.Latent Labs specializes in the development of generative AI models that make biology programmable, focusing on applications in molecular biology. Their core product offerings center around advanced computational tools that enable the design and optimization of biological entities, such as antibodies and enzymes, and facilitate genetic engineering processes. These solutions empower pharmaceutical companies and biotech firms by providing control over biological systems, addressing challenges in health and sustainability, and are relevant in creating novel therapeutics and efficient biological processes. Latent Labs serves clients primarily in North America and Europe, engaging with industry leaders in healthcare and biotechnology.Latent Labs generates revenue through partnerships and collaborations within the biotechnology and pharmaceutical sectors. The company engages in B2B transactions structured around strategic partnerships that involve licensing their generative AI technology or providing specialized services. Clients may work with Latent Labs to co-develop specific biotechnological products, resulting in revenue-sharing agreements based on successful outcomes. The recent funding further supports the scaling of its offerings and development of flagship technologies, reflecting the commercial potential of its approach to programmable biology.Latent Labs plans to use the USD 40.00 mn raised in Series A funding to enhance its AI capabilities, expand its team, and foster collaborations with biotech and pharmaceutical companies. The company aims to launch new products designed to optimize gene editing processes, with anticipated releases in late 2025. Additionally, Latent Labs will target expansion into Asia and South America by mid-2026, aiming to establish strategic partnerships in these new markets.

## Funding rounds

- Series A, Dec 1, 2024, $40M — Sofinnova Partners, Radical Ventures, Kindred Capital, 8VC, Isomer Capital, Pillar, Flying Fish
- Seed, date not disclosed — Kindred Capital, 8VC, Pillar

## Investors

- Kindred Capital (https://capitalatlas.ai/funds/kindred-capital) — Seed, Series A
- 8VC (https://capitalatlas.ai/funds/8vc) — Seed, Series A
- Pillar (https://capitalatlas.ai/funds/pillar) — Seed, Series A
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Radical Ventures (https://capitalatlas.ai/funds/radical-ventures) — Series A
- Isomer Capital (https://capitalatlas.ai/funds/isomer-capital) — Series A
- Flying Fish (https://capitalatlas.ai/funds/flying-fish) — Series A